TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01218451

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal 13-valent conjugate vaccine
Description: 0.5 mL dose, subcutaneous administration in right anterolateral thigh

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal 13-valent conjugate vaccine
Description: 0.5 mL dose, subcutaneous administration in right anterolateral thigh

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal 13-valent conjugate vaccine
Description: 0.5 mL dose, subcutaneous administration in right anterolateral thigh

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine
Description: 0.5 mL dose, subcutaneous administration in right anterolateral thigh

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine
Description: 0.5 mL dose, subcutaneous administration in right anterolateral thigh

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine
Description: 0.5 mL dose, subcutaneous administration in right anterolateral thigh
Study: NCT02022592

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Study: NCT03652506

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: regional oxymetry probe
Description: The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: regional oxymetry probe
Description: The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
Study: NCT04274153

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gardasil9
Description: Two doses of the HPV vaccine across a 12 month period (two doses of 0.5mL).
Study: NCT01238835

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SAPIEN XT™ Transapical aortic valve replacement
Description: Transcatheter aortic valve implantation via the transapical approach
Study: NCT00908648

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Narrow Band Imaging
Description: Narrow Band Imaging
Study: NCT03652506

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: regional oxymetry probe
Description: The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
Study: NCT01966588

Intervention type: OTHER
Intervention: Blood samples for whole genomic/transcriptomic sequencing
Description: Participants in the Metabolic Arm will receive one blood draw, while participants in the Neutropenia Arm will receive a total of three blood draws: one at baseline, another 3 months later, and one 1 year later, with the possibility of further follow-up.
Study: NCT03652506

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus Lumborum block
Description: Ultrasound guided unilateral anterior Quadratus Lumborum block with 20 ml %0.25 bupivacaine+The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
Study: NCT01966588

Intervention type: OTHER
Intervention: Blood samples for whole genomic/transcriptomic sequencing
Description: Participants in the Metabolic Arm will receive one blood draw, while participants in the Neutropenia Arm will receive a total of three blood draws: one at baseline, another 3 months later, and one 1 year later, with the possibility of further follow-up.

Intervention type: OTHER
Intervention: UKU Side Effect Rating Scale
Description: Clinician-rated scale of psychic, neurological, autonomic, and other side effects related to psychotropic drugs; ratings are based on a 10-30 minute interview with each participant.
Study: NCT03652506

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic Epidural block
Description: Thoracic Epidural block with 20 ml %0.25 bupivacaine+The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
Study: NCT01914991

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dynamic extension contracture orthotic
Description: A dynamic orthosis was constructed in the experimental group using the same style of dynamic extension contracture orthotic. A mobilizing force of 250 - 300 gm/cm2 was set in each one. Patients were instructed to wear it for at least 6 hours per day and then removed it for ADL (Activity Daily Living). A static orthosis was constructed using orfitcast material to the maximum, pain-free length allowed by the tissues at night. Static and dynamic orthoses were checked once a week and adjusted as necessary.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional treatment Physical Therapy
Description: Traditional treatment was applied to one control group. The treatment consisted of 10 minutes of local thermotherapy (paraffin), active exercises at the PIPJ and DIPJ (Distal interphalangeal joint), 3 sets of 15 repetitions of each exercise extending and flexing of the PIPJ with metacarpophalangeal joint from 0° to 90° respectively. Distal interphalangeal joint exercises were conducted with identical repetitions. The metacarpophalangeal joint and PIPJ exercises took place at 0 ° and involved stretching (5 sets of 3 reps, holding for 10 seconds) and Therapeutic U.S (0.8 w/cm2 / 7 minutes).
Study: NCT03867565

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional intervention
Description: Indirect calorimetry Weight development Nitrogen balance Food records Physical activity Nutritional risk screening and assessment Inflammatory response Wound healing as number of days from burn to no more need of dressing changes via health care facility Frequency of infections as the number, sort, dose, and length of antibiotic treatment(s) from burn to no more need of dressing changes via health care facility
Study: NCT00661206

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Patients on clopidogrel therapy at 6 months after implantation of a drug-eluting stent will be randomized to an additional 6 month period of clopidogrel 75mg per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients randomized in this group will receive placebo for 6 months.
Study: NCT00695188

Intervention type: DRUG
Group type: OTHER
Intervention: methotrexate
Description: oral administration Escalating dose (15, 20, 25 mg)
Study: NCT03844529

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sunmax FULLSGEN with Lidocaine
Description: Subject who voluntarily sign the informed consent form (day -14\~1) will be randomly assigned to investigational or control group and have intradermal allergy test. After the injection treatment by randomly choosing the device, every subject would have 6 follow-up visits.
Study: NCT04224272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZW25 (Zanidatamab)
Description: Administered intravenously
Study: NCT02946047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib 2 MG
Description: 2mg on days 1, 8 and 15 for three 28 days cycles, then be reviewed by DSMB and based upon their recommendation patients will receive ixazomib once weekly for 12 weeks or ixazomib 2 mg on days 1, 8 and 15 for three 28 days cycles. Visits 3-15 will have a window of ± 3 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib 3 MG
Description: 3 mg on days 1, 8 and 15 for three 28 days cycles, then be reviewed by DSMB and based upon their recommendation patients will receive ixazomib once weekly for 12 weeks or ixazomib 3 mg on days 1, 8 and 15 for three 28 days cycles. Visits 3-15 will have a window of ± 3 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib 4 MG
Description: 4 mg on days 1, 8 and 15 for three 28 days cycles, then be reviewed by DSMB and based upon their recommendation patients will receive ixazomib once weekly for 12 weeks or ixazomib 4 mg on days 1, 8 and 15 for three 28 days cycles. Visits 3-15 will have a window of ± 3 days.
Study: NCT01011660

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine, Telmisartan, Amiloride Compound , Simvastatin
Description: Amlodipine; Telmisartan; Amiloride Compound; Simvastatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine, Telmisartan, Amiloride Compound , Simvastatin
Description: Amlodipine; Telmisartan; Amiloride Compound; Simvastatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine, Telmisartan, Amiloride Compound , Simvastatin
Description: Amlodipine; Telmisartan; Amiloride Compound; Simvastatin
Study: NCT03844529

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sunmax FULLSGEN with Lidocaine
Description: Subject who voluntarily sign the informed consent form (day -14\~1) will be randomly assigned to investigational or control group and have intradermal allergy test. After the injection treatment by randomly choosing the device, every subject would have 6 follow-up visits.
Study: NCT02868801

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: same intervention as the experimental group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin SR tablet 165mg/day
Description: According to the efficacy and safety in titration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin SR tablet 330mg/day
Description: According to the efficacy and safety in titration
Study: NCT04224272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Administered as an intramuscular injection
Study: NCT03242772

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amphetamine
Description: Study drug will be administered in the morning. Treatment will be initiated at 1 tablet = 3.1 mg or 0 mg of mixed amphetamine. Doses will be flexibly titrated upward and may be decreased or stopped at any time.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ESDM informed parent coaching
Description: All participants will receive 8 weekly parent child therapy sessions will be delivered by a therapist trained in parent coaching and ESDM principles and strategies and utilizing a therapy manual,(includes coaching for behavior management and handouts).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: ESDM informed parent coaching
Description: All participants will receive 8 weekly parent child therapy sessions will be delivered by a therapist trained in parent coaching and ESDM principles and strategies and utilizing a therapy manual,(includes coaching for behavior management and handouts).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Matched placebo tablets will be administered in the morning and provided for 11 weeks . The tablets will be titrated in the same way as the active drug and may be stopped at any time.
Study: NCT01011660

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine, Telmisartan, Amiloride Compound , Simvastatin
Description: Amlodipine; Telmisartan; Amiloride Compound; Simvastatin
Study: NCT01770379

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Secukinumab (AIN457)
Description: Secukinumab is a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a messenger protein in the body) called Interleukin 17 (IL-17)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Secukinumab (AIN457)
Description: Secukinumab is a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a messenger protein in the body) called Interleukin 17 (IL-17)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00421187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (AmBisome®)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal amphotericin B (AmBisome®)
Study: NCT01882517

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Yogurt that contains plant stanol esters

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo yogurt
Study: NCT05516784

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Comparison of platelet reactivity between clopidogrel and ticagrelor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Comparison of platelet reactivity between clopidogrel and ticagrelor
Study: NCT00695188

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: 25 mg oral administration
Study: NCT00487045

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hem-Avert Perianal Stabilizer
Description: Hem-Avert Perianal Stabilizer, TNP-01L, single-use, disposable, sterile, individually packaged instrument
Study: NCT00853593

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pacing Lead
Description: implant and follow-up of study device
Study: NCT01961076

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: overnight nutrition regime
Description: Patients receive the specified overnight nutrition regimen
Study: NCT05516784

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Comparison of platelet reactivity between clopidogrel and ticagrelor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Comparison of platelet reactivity between clopidogrel and ticagrelor
Study: NCT03552211

Intervention type: DRUG
Intervention: biotin
Description: This is a national, academic, observational and retrospective study comparing one group of progressive MS patients with high dose biotin to another group without this treatment using a propensity score, in intention to treat.
Study: NCT01364662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPN-810
Description: administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPN-810
Description: administered orally
Study: NCT01961076

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: overnight nutrition regime
Description: Patients receive the specified overnight nutrition regimen

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: overnight nutrition regime
Description: Patients receive the specified overnight nutrition regimen
Study: NCT00622700

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Teriflunomide
Description: Film-coated tablet Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriflunomide
Description: Film-coated tablet Oral administration
Study: NCT02868801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin SR tablet 660mg/day
Description: According to the efficacy and safety in titration.
Study: NCT03058276

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Retrieval-Extinction Learning
Description: The intervention consists of the accomplishment of the task of approach-avoidance of alcohol during 4 days of training. Subjects are instructed to respond with an approach movement (pulling a lever) to neutral images and to respond with avoidance movement (pushing the lever) to images of alcohol.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Retrieval-Extinction Learning
Description: The intervention consists of the accomplishment of the task of approach-avoidance of alcohol during 4 days of training. Subjects are instructed to respond with an approach movement (pulling a lever) to neutral images and to respond with avoidance movement (pushing the lever) to images of alcohol.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rTMS
Description: Previous to rTMS completion, MRI scans were performed in order to determinate the motor threshold trough 1Hz stimuli and locate the desired area with the neuronavigator. Motor threshold is defined as the stimulus with less intensity, able to generate a motor potential of at least 50 µV in 10 trials. Next, patients were called for 5 times per week, along 2 weeks, for receiving brain stimulation with Magstim Rapid coil. rTMS is performed at 10 Hz, during 4.9 seconds,for each set of stimuli (20), with a interval between sets of 30 seconds.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: SAM
Description: Previous to rTMS completion, MRI scans were performed in order to determinate the motor threshold trough 1Hz stimuli and locate the desired area with the neuronavigator. Motor threshold is defined as the stimulus with less intensity, able to generate a motor potential of at least 50 µV in 10 trials. Next, patients were called for 5 times per week, along 2 weeks, for receiving brain stimulation with SAM coil.
Study: NCT02532816

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrient dense complementary foods
Description: Mothers/caregivers will receive optimized CFRs to improve children diets and fortified biscuits (3 types of biscuit) for 6 days per week (in 12 months).~Nutrition eduction for mothers/caregivers. Monthly body weight and length/height measurements

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nutrient dense complementary foods
Description: Mothers/caregivers will receive optimized CFRs to improve children diets and fortified biscuits (3 types of biscuit) for 6 days per week (in 12 months).~Nutrition eduction for mothers/caregivers. Monthly body weight and length/height measurements

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutrient dense complementary foods
Description: Mothers/caregivers will receive optimized CFRs to improve children diets and fortified biscuits (3 types of biscuit) for 6 days per week (in 12 months).~Nutrition eduction for mothers/caregivers. Monthly body weight and length/height measurements
Study: NCT01553695

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionary
Description: Subjects have to fill out a booklet of questionnaires

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionary
Description: Subjects have to fill out a booklet of questionnaires
Study: NCT03634852

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin hydrochloride 0.5% eye drops
Description: were prescribed four times a day for 1-month postoperatively

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 0.1% eye drops
Description: were prescribed four times a day for 1-month postoperatively

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intracameral Moxifloxacin 0.1%
Description: Auromox (0.5%): is a sterile clear yellow pale colored preservative free isotonic ophthalmic solution with pH 6.0 to 7.5 and osmolarity 620 -320 milliosmol ( mOsm).The sterile Auromox vial contains 1cc Moxifloxacin hydrochloride 5.45 mg equivalent to 5mg of Moxifloxacin. This product is manufactured by Aurolab an Indian pharmaceutical company. Auromox is available in many countries including Iraq.~Each vial enough for 15 different patients by using a sterile needle and 5cc syringe. By the sterile hand's, the surgeon draws the whole 1cc of Moxifloxacin 0.5% and diluted with 4 cc of balanced salt solution (BSS) to get 5 mg in 5 cc (0.1%) then draw 0.2 cc for each patient.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Subconjunctival Triamcinolone acetonide 4 mg /0.4 ml
Description: Aurocort is a preservative-free Triamcinolone acetonide (40 mg /1cc), with along acting depot preparation of triamcinolone in 1cc vial also the product of Aurolab company and commercially available in our country.~The whole 1cc had been drawn and diluted with 3cc of BSS and SC injection of 4 mg in 0.4 cc of Triamcinolone was given (as a final step in the surgery) 6mm from the limbus usually an inferotemporal site that is easily accessible and the plaque that formed will be not visible within palpebral fissure
Study: NCT04681742

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CO-OP Group
Description: CO-OP focuses on learning of a global problem-solving strategy, Goal-Plan-Do-Check (GPDC), within the performance of participant-chosen goals. Use of a broadly applicable strategy and meaningful activity ensures the intervention is salient to the participant and increases likelihood of transfer. Uniquely, therapists applying CO-OP use guided discovery methods, such as asking a series of probing questions, to support participants in analyzing their own performance of a given task and generating potential solutions for improving performance. Participants become equipped with these skills through repetitive application of the GPDC process. First, participants identify a specific goal (Goal). Then, participants consider a detailed plan (Plan) for accomplishing the goal. By carrying out the plan (Do) and critically analyzing the results (Check), participants determine how the plan worked. The intervention focuses on learning GPDC with gradual withdrawal of guided discovery methods.
Study: NCT01097564

Intervention type: GENETIC
Intervention: COL4A1 genetic testing
Description: genetic testing
Study: NCT03745391

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: MULTIMODAL MAGNETIC RESONANCE (Multimodal MR)
Description: After randomization, a MULTIMODAL MR will be performed to select treatment patient
Study: NCT03552211

Intervention type: OTHER
Intervention: propensity score
Description: This is a national, academic, observational and retrospective study comparing one group of progressive MS patients with high dose biotin to another group without this treatment using a propensity score, in intention to treat.
Study: NCT02885857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shenyan Kangfu Tablet
Description: Observation period: 24 weeks. The dosage regimen: each piece weighs 0.48 g. 5 / time, 3 times daily, orally after dinner.
Study: NCT03372551

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: somofilcon A 1 day test lens
Description: Contact lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: somofilcon A 1 day test lens
Description: Contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: somofilcon A 1 day control lens
Description: Contact lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: somofilcon A 1 day control lens
Description: Contact lens